Johnson & Johnson said to pay $2.2 bln to end U.S. marketing probes
WASHINGTON Nov 4 (Reuters) - Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses, a person familiar with the settlement said on Monday.
The settlement with the company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug Natrecor, said the person, who spoke on condition of anonymity.
- Pope attacks mega-salaries and wealth gap in peace message
- Air strike kills 15 civilians in Yemen by mistake: officials
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study
- South Africa admits error over 'schizophrenic' Mandela signer |